FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362521119> ?p ?o ?g. }

• W4362521119 endingPage "708" @default.
• W4362521119 startingPage "706" @default.
• W4362521119 abstract "BACKGROUND Chronic HBV infection is the leading cause of HCC, particularly in Asia and Africa. Despite demonstrating response rates ranging from 15% to 30% in patients with HCC, immune checkpoint inhibitor (ICI) immunotherapy has not achieved the optimal efficacy as observed in melanoma.1 Recent studies reveal that immunotherapies may be more effective in viral etiologies, particularly HBV, than nonviral HCC,2,3 while there is no difference related to the etiology of HCC in patients receiving tyrosine-kinase inhibitor therapy.2 These findings suggest the profound implication of the tumor microenvironment (TME) in response to immunotherapies. It is thus intriguing to ask why HBV+-HCC has a better response to ICI therapy, what are the roles of HBV-specific immune cells in modulating the debilitated immune in HCC, and whether it is possible to revive the HBV-related immune for anticancer therapy. Does HBV-specific immune sculpture the immune in TME of HCC? Multi-omics studies, including single-cell RNA sequencing, cytometry by time-of-flight, and multiplexed immunohistochemistry, have shown that the TME of HBV+-HCC is immune hot but highly immunosuppressive characterized by the enrichment of exhausted CD8+ T cells, regulatory T cells (Treg), and HBV-specific CD8+ T cells recognizing diverse HBV-derived epitopes, including tissue-resident memory T cells (TRM).4,5 In addition, Treg and TRM from HBV+-HCC express more PD-1 and are functionally immune suppressive and exhausted than nonviral HCC. Clinically, Treg cells in the TME were associated with a poor prognosis, while HBV-specific TRM cells were associated with a good prognosis in HCC.4,5 Together, these studies suggest that chronic HBV infection usually sculptures a hot but debilitated immune status favoring tumor development in the liver. How chronic HBV infection modulates immune profiles in the TME of HCC? You et al6 combined epigenomic and transcriptomic approaches to delineate the HBV-specific Treg, CD8+ exhausted T cells (Tex), and HBV-specific effector memory CD8 T cells and characterized their T-cell receptor repertoire clonality and specificity in a cohort of 43 patients with HBV+-HCC and 11 patients with HBV--HCC. They found a shared epigenomic program that regulates the differentiation of HBV-specific Treg and Tex and the HBV-related Treg-CTLA4 and CD8+Tex-TOX subsets in the TME of HCC. Meanwhile, a significant proportion of HBV-specific effector memory CD8 T cells and HBV-related FGFBP2+ CD8+ T cells were governed by shared transcription factor motifs of AP1, NFE2, and BACH1/2,6 suggesting the role of chronic HBV infection in sculpturing the immune profile of TME (Figure 1).FIGURE 1: The epigenomic programs leash and unleash the HBV-associated immune for tumor development and antitumor immunotherapy, respectively. Created with BioRender.com. Abbreviations: ICI, immune checkpoint inhibitor; TCR, T-cell receptor; TME, tumor microenvironment; Treg, regulatory T cells.Can we reinvigorate the HBV-induced immune from debilitation to empowered anti-tumor immunity? Clinically, Treg cells in the TME were associated with a poor prognosis, while HBV-specific TRM cells were associated with a good prognosis in HCC.4,5 Furthermore, HBV-specific CD8+T cells expressed FASLG, linked to the FASLG-FAS cell-to-cell communication network involving HBV-specific Treg cells and tumor cells.6 These findings hold substantial implications for targeting immunosuppressive cells like HBV-related Treg in TME to improve the efficacy of immunotherapy. Indeed, a recent study shows the treatment with a CCR4 antagonist blocked intratumoral Treg accumulation, overcame sorafenib resistance, rescued CD8+ T-cell function, and sensitized tumors to PD-1 checkpoint blockade in HBV+-HCC.7 In contrast, the anti-PD1 treatment led to an increase in the number and size of tumor nodules, which correlated with increased hepatic CD8+PD1+TOX+ T cells in NASH-HCC.3 These phenomena may partially explain why ICI therapy is more effective in patients with HBV+-HCC than in those with HBV−-HCC. Future challenges The discovery by You et al6 sheds light on the potential for virus-specific T cells to serve as elicitors of anti-tumor immunity in viral-associated HCC. However, the discrepancies in ICI responsiveness between HBV+-HCC and HCV+-HCC has not been fully explained. In recent years, more and more patients with chronic hepatitis B have achieved clinical HBV cured (HBsAg seroclearance), particularly after a finite nucleos(t)ide analog therapy.8 For these patients, it is unclear whether the “epigenetic scar” seen in patients cured of chronic hepatitis C9,10 is also present. As such, how are the potential impacts of the HBV-specific immune on immunotherapies of HCC in patients with HBsAg seroclearance? Nevertheless, reanimating the long-term infection-induced exhausted immune cells to treat virus-related cancers provides a promising paradigm for developing targeted immunotherapies." @default.
• W4362521119 created "2023-04-06" @default.
• W4362521119 creator A5053232339 @default.
• W4362521119 creator A5078448162 @default.
• W4362521119 date "2023-04-05" @default.
• W4362521119 modified "2023-10-14" @default.
• W4362521119 title "More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC" @default.
• W4362521119 cites W2767742777 @default.
• W4362521119 cites W2810928105 @default.
• W4362521119 cites W3118328775 @default.
• W4362521119 cites W3138484572 @default.
• W4362521119 cites W3169705253 @default.
• W4362521119 cites W3172878008 @default.
• W4362521119 cites W3180432427 @default.
• W4362521119 cites W3188748295 @default.
• W4362521119 cites W3201295484 @default.
• W4362521119 cites W4362507453 @default.
• W4362521119 doi "https://doi.org/10.1097/hep.0000000000000393" @default.
• W4362521119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37013921" @default.
• W4362521119 hasPublicationYear "2023" @default.
• W4362521119 type Work @default.
• W4362521119 citedByCount "1" @default.
• W4362521119 countsByYear W43625211192023 @default.
• W4362521119 crossrefType "journal-article" @default.
• W4362521119 hasAuthorship W4362521119A5053232339 @default.
• W4362521119 hasAuthorship W4362521119A5078448162 @default.
• W4362521119 hasBestOaLocation W43625211191 @default.
• W4362521119 hasConcept C167672396 @default.
• W4362521119 hasConcept C203014093 @default.
• W4362521119 hasConcept C2776107976 @default.
• W4362521119 hasConcept C2777701055 @default.
• W4362521119 hasConcept C2780851360 @default.
• W4362521119 hasConcept C502942594 @default.
• W4362521119 hasConcept C71924100 @default.
• W4362521119 hasConcept C8891405 @default.
• W4362521119 hasConceptScore W4362521119C167672396 @default.
• W4362521119 hasConceptScore W4362521119C203014093 @default.
• W4362521119 hasConceptScore W4362521119C2776107976 @default.
• W4362521119 hasConceptScore W4362521119C2777701055 @default.
• W4362521119 hasConceptScore W4362521119C2780851360 @default.
• W4362521119 hasConceptScore W4362521119C502942594 @default.
• W4362521119 hasConceptScore W4362521119C71924100 @default.
• W4362521119 hasConceptScore W4362521119C8891405 @default.
• W4362521119 hasIssue "3" @default.
• W4362521119 hasLocation W43625211191 @default.
• W4362521119 hasLocation W43625211192 @default.
• W4362521119 hasLocation W43625211193 @default.
• W4362521119 hasOpenAccess W4362521119 @default.
• W4362521119 hasPrimaryLocation W43625211191 @default.
• W4362521119 hasRelatedWork W2079588331 @default.
• W4362521119 hasRelatedWork W2112727616 @default.
• W4362521119 hasRelatedWork W2387430262 @default.
• W4362521119 hasRelatedWork W2884525857 @default.
• W4362521119 hasRelatedWork W3215438668 @default.
• W4362521119 hasRelatedWork W4200022043 @default.
• W4362521119 hasRelatedWork W4296613612 @default.
• W4362521119 hasRelatedWork W4307869277 @default.
• W4362521119 hasRelatedWork W4322720888 @default.
• W4362521119 hasRelatedWork W4366149851 @default.
• W4362521119 hasVolume "78" @default.
• W4362521119 isParatext "false" @default.
• W4362521119 isRetracted "false" @default.
• W4362521119 workType "article" @default.